Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00742963 Org: User:
Start: 08/31/08 End: 10/31/13 Due: 10/31/14

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01746979 Org: User:
Start: 12/31/12 End: 05/31/16 Due: 05/31/17

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02047500 Org: User:
Start: 01/31/14 End: 05/31/16 Due: 05/31/17

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01864538 Org: User:
Start: 05/31/13 End: 09/30/15 Due: 09/30/16

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06014502 Org: User:
Start: 09/07/23 End: 12/31/27 Due: 12/31/28

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02093962 Org: User:
Start: 06/30/14 End: 05/31/16 Due: 05/31/17

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Phase: N/A Priority: Normal
NCT ID: NCT06782555 Org: User:
Start: 01/08/25 End: 01/31/28 Due: 01/31/29

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01144455 Org: User:
Start: 06/30/10 End: 12/31/14 Due: 12/31/15